TITLE:
Phase II Study in Patients With Recurrent Non-Small-Cell Lung Cancer

CONDITION:
Non-Small-Cell Lung Cancer

INTERVENTION:
Cetuximab

SUMMARY:

      Determine tumor response rate and time to disease progression, survival and safety in total
      populations.
    

DETAILED DESCRIPTION:

      To determine the tumor response rate and time to disease progression, survival and safety in
      the EGFR-positive, EGFR-negative and total populations.
    

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria

          1. Subjects with recurrent or progressive NSCLC with either present or prior histologic
             confirmation or pathologic confirmation of NSCLC

          2. Subjects receiving 1 or more prior chemotherapy regimens for the treatment of
             recurrent/metastatic disease, including at least 1 platinum-based combination

          3. Unidimensionally measurable NSCLC

          4. Subjects with tumor tissue available for EGFR assessment

          5. ECOG performance status of 0 or 1

          6. Subjects with asymptomatic brain metastasis were eligible; however, they must have
             completed radiotherapy/radiosurgery at least 3 weeks prior to enrollment and have
             been off steroids

        Exclusion Criteria

          1. Women of childbearing potential who were unwilling or unable to use an acceptable
             method to avoid pregnancy for the entire study period and for up to 4 weeks after the
             study. Male subjects must also have agreed to use effective contraception

          2. Women of childbearing potential using a prohibited contraceptive method

          3. Women who were pregnant or breastfeeding

          4. Women with a positive pregnancy test on enrollment or prior to study drug
             administration.
      
